close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
FDA Approves Merck’s WELIREG® (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Research on Novel Treatment Approaches and Scientific Advances From Merck’s Broad and Differentiated Oncology Portfolio and Pipeline to be Presented at ASCO 2025
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Participate in the Bank of America 2025 Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces First-Quarter 2025 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck’s Investigational Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Demonstrates Noninferior Pharmacokinetics Compared to Intravenous (IV) KEYTRUDA® (pembrolizumab) in Pivotal 3475A-D77 Trial
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
European Commission (EC) Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and Pneumococcal Pneumonia in Adults
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Data at ACC.25 Highlight Innovative Advancements and Commitment to Improving Outcomes for People Living with Cardiovascular Disease
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Unveils New Facility to Increase Vaccine Production Capacity
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Participate in the TD Cowen 45th Annual Health Care Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
WELIREG® (belzutifan) Receives First European Commission Approval for Two Indications
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Phase 3 waveLINE-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Receives Positive EU CHMP Opinion for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final Analysis
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
FDA Grants Priority Review to Merck’s Application for WELIREG® (belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (PPGL)
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck’s GARDASIL® Receives Expanded Approval for Males in China
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
News headline image
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection
From Merck & Co., Inc.
Via Business Wire
Tickers MRK
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.